How the flu could leave you at the mercy of killer fungus aspergillosis
One in five patients admitted to intensive care with flu may contract a lethal fungal infection in their lungs called aspergillosis which can resist medicine’s best drugs. (Source: the Mail online | Health)
Source: the Mail online | Health - May 14, 2019 Category: Consumer Health News Source Type: news
Could humble tulips harbour a secret killer? John believes infected compost caused his wife's death
John Pibworth, 77, a retired flooring contractor from Shropshire, believes infected compost was responsible for infecting his late wife, Ann, with aspergillosis. (Source: the Mail online | Health)
Source: the Mail online | Health - April 30, 2019 Category: Consumer Health News Source Type: news
Researchers' breakthrough in tackling challenge of antifungal resistance
(Swansea University) Ground-breaking work by university experts in Tennessee, Texas and Swansea is helping develop a better understanding of the growing threat posed by antifungal drug resistance. Invasive aspergillosis is a devastating disease caused by breathing in small airborne spores of the fungus Aspergillus fumigatus and it is a condition where drug resistance has been encountered. They have just released a paper revealing how they have been able to identify a previously uncharacterized genetic mutation in clinical isolates that leads to resistance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 3, 2019 Category: International Medicine & Public Health Source Type: news
9th Advances Against Aspergillosis and Mucormycosis
Date: Monday, March 4, 2019Year: 2020Location: Lugano, SwitzerlandContent-type: current_conferences (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - March 4, 2019 Category: Respiratory Medicine Authors: helenfindon Source Type: news
Diagnosis and treatment of chronic pulmonary aspergillosis
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 26, 2019 Category: Respiratory Medicine Authors: helenfindon Source Type: news
Pulmatrix wins FDA nod for PhII trial of inhaled anti-fungal therapy
Pulmatrix (NSDQ:PULM) said today that the FDA approved a Phase II trial of the company’s inhaled formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in people with asthma.
The Lexington, Mass.-based company plans to kick off the trial in the first half of 2019, with top-line data expected in the second quarter of 2020.
Get the full story at our sister site, Drug Delivery Business News.
The post Pulmatrix wins FDA nod for PhII trial of inhaled anti-fungal therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 7, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Featured Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news
Clinical Fellow - Infectious Diseases and Aspergillosis
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - December 21, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Journal for Antimicrobial Chemotherapy-Medical Mycology Joint Issue
Aspergillosis continues to be a frequent cause of opportunistic infection and mortality among patients with suppressed immunity and those with airway diseases. This virtual issue is a joint endeavour between the Journal of Antimicrobial Chemotherapy and Medical Mycology to highlight the diagnosis and the clinical aspects of the management of chronic aspergillosis as well as the relatively new phenomenon of emergent azole resistance.ISHAM hope the reader will find the collection useful in gaining new insights into aspergillosis from a laboratory and clinical perspective. Wednesday, December 19, 2018 - 18:19Updates (So...
Source: The Aspergillus Website - updates - December 19, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Isavuconazole good value for money in invasive aspergillosis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2018 Category: Drugs & Pharmacology Source Type: news
Allergic bronchopulmonary aspergillosis complicating COPD is associated with a higher exacerbation rate and a distinct pattern on chest CT scan compared to COPD
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 23, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 23, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
IgE immunadsorption in allergic bronchopulmonary aspergillosis: A pilot study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 23, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Serum level directed itraconazole therapy in allergic bronchopulmonary aspergillosis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 23, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Treatment outcome in patients with chronic pulmonary aspergillosis by azole-resistant aspergillus fumigatus
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 23, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
An Optimized, Large Scale Generation and Validation of Aspergillus-Specific T Lymphocytes for the Management of Invasive Aspergillosis in Immunocompromised Patients
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 19, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
A Ball of Fun: Allergic Bronchopulmonary Aspergillosis Presenting as a Pneumothorax
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 19, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Fungal Hyphae-Containing Eosinophilic Bronchial Mucus Plugs in Patients with Allergic Bronchopulmonary Aspergillosis Without Asthma Symptoms
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 19, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Phenotypes of Allergic Bronchopulmonary Aspergillosis Identified by Cluster Analysis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 19, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Study on the Clinical and Immunological Characteristics of Fungal Sensitive Asthma and Allergic Bronchopulmonary Aspergillosis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 16, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Omalizumab Treatment in Patients with Cystic Fibrosis (CF) and Allergic Bronchopulmonary Aspergillosis (ABPA): a Case Series
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 16, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Communication and Digital Content Officer (National Aspergillosis Centre)
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 25, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Carriers of cystic fibrosis may be at greater risk for allergic bronchopulmonary aspergillosis
Tue, 10/09/2018 - 11:45News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 9, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Real-life experience of Omalizumab in adult Cystic Fibrosis patients with allergic severe asthma and Allergic Bronchopulmonary Aspergillosis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 27, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
The characteristics of serum hydroxy-eicosatetraenoic acids in allergic bronchopulmonary aspergillosis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 19, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
New ESCMID/ERS guidelines for diagnosis and treatment of chronic pulmonary aspergillosis
Wednesday, July 18, 2018 - 13:13Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 18, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Invasive aspergillosis in haematology New guidelines
Wednesday, July 18, 2018 - 13:10Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 18, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Recent advances in allergic bronchopulmonary aspergillosis complicating asthma
Wednesday, July 18, 2018 - 13:05Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 18, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Recent Advances in Allergic Bronchopulmonary Aspergillosis Complicating Cystic Fibrosis
Wednesday, July 18, 2018 - 13:02Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 18, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Pulmatrix touts data from first-in-human trial of inhaled anti-fungal therapy
Pulmatrix (NSDQ:PULM) said today that all dosing and follow-up visits have finished for its first-in-human study of an inhaled formulation of itraconazole as a treatment of allergic bronchopulmonary aspergillosis in people with asthma.
The inhaled iSperse formulation, called Pulmazole, was well-tolerated, according to the Lexington, Mass.-based company. Pulmatrix plans to launch a Phase II trial of its ABPA therapy in the fourth quarter this year.
Get the full story at our sister site, Drug Delivery Business News.
The post Pulmatrix touts data from first-in-human trial of inhaled anti-fungal therapy appeared first on ...
Source: Mass Device - July 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat Pulmatrix Inc. Source Type: news
Aspergillosis Trust
Post date: 3 Jul 2018 - 9:38am (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 3, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Chronic Pulmonary Aspergillosis Network (CPAnet)
Mon, 07/02/2018 - 13:13News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 2, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Two point-of-care tests for invasive aspergillosis launched
Thu, 06/21/2018 - 16:05News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 21, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Comment on "Sterilizing immunity in the lung relies on targeting fungal apoptosis-like programmed cell death"
Shlezinger et al. (Reports, 8 September 2017, p. 1037) report that the common fungus Aspergillus fumigatus, a cause of aspergillosis, undergoes caspase-dependent apoptosis-like cell death triggered by lung neutrophils. However, the technologies they used do not provide reliable evidence that fungal cells die via a protease signaling cascade thwarted by a fungal caspase inhibitor homologous to human survivin. (Source: ScienceNOW)
Source: ScienceNOW - June 21, 2018 Category: Science Authors: Aouacheria, A., Cunningham, K. W., Hardwick, J. M., Palkova, Z., Powers, T., Severin, F. F., Vachova, L. Tags: Immunology, Microbiology t-comment Source Type: news
Consultant in Infectious Diseases (National Aspergillosis Centre, UK)
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 15, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Clinical Fellow - Infectious Diseases and Aspergillosis
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 4, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Clinical Fellow – Infectious Disease and National Aspergillosis Centre
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - May 29, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news
What Causes Hyponatremia?
Discussion
Normal kidneys regulate water balance to maintain a plasma osmolality of 275-290 mOsm/kg normally. Thirst and arginine vasopressin or antidiuretic hormone (ADH) are the primary regulators of plasma osmolality. ADH is made in the hypothalamus and released by the posterior pituitary gland. ADH acts on the kidney’s distal collecting duct to increase water reabsorption. ADH is appropriately released in hypovolemic states, such as dehydration caused by gastroenteritis. ADH has an ~10 minute half-life and therefore can respond to rapid changes in volume status. Sodium balance is regulated by aldosterone (as part...
Source: PediatricEducation.org - April 23, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Severe fever with thrombocytopenia syndrome complicated by invasive aspergillosis
Tue, 03/27/2018 - 14:06News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - March 27, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news
Latest ESCMID-ECMM-ERS Clinical Guidelines for Aspergillosis Published
Mon, 03/26/2018 - 15:51News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - March 26, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Lessons to be learned from an invasive aspergillosis outbreak in a Japanese haematology ward
Thu, 03/22/2018 - 13:42News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - March 22, 2018 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
8th Advances Against Aspergillosis, Lisbon, Portugal
8th Advances Against Aspergillosis took place 1-3rd February 2018 in the pleasant sunshine of Lisbon, Portugal, leaving the snow of Manchester 2016 far behind. This is the only conference focussing on this fungal disease and has been running since 2004, attracting 400 researchers from all over the world and since 2012 has also been holding a parallel meeting for patients with aspergillosis and their carers.Post date: 7 Mar 2018 - 3:16pm (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - March 7, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Single Aspergillus fumigatus inoculation induces aspergillosis in falcons
Thu, 02/22/2018 - 10:29News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 22, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news
Why does ibrutinib carry a risk of cerebral aspergillosis?
Wednesday, February 21, 2018 - 14:33Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 21, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news
How to get rid of black mould and damp: Avoid catching aspergillus with these five steps
BLACK mould and damp is a common problem during this time of year and respiratory problems, allergies, and asthma can be a result of infestations. Inhaling tiny bits of mould can also cause a condition called aspergillosis. The NHS explains how best to get rid of mould and damp problems. (Source: Daily Express - Health)
Source: Daily Express - Health - February 19, 2018 Category: Consumer Health News Source Type: news
Genetics of Aspergillosis
Friday, February 16, 2018 - 15:35Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 16, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news
Why and when aspergillosis first appears in cystic fibrosis patients?
Thursday, February 15, 2018 - 10:48Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 15, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news
The Human Lung and Aspergillosis: You are what you Breathe in?
Thursday, February 15, 2018 - 10:30Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 15, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news
Managing breakthrough invasive aspergillosis
Thursday, February 15, 2018 - 10:19Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 15, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news
Recent Advances in Diagnosis and Treatment of Allergic Aspergillosis
Thursday, February 15, 2018 - 10:18Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 15, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news
Pulmatrix doses first patient in Ph1 Pulmazole trial
Pulmatrix (NSDQ:PULM) said today that the first patient was treated in a first-in-human study of Pulmazole – an inhaled formulation of the anti-fungal drug, itraconazole.
The Lexington, Mass.-based company is evaluating its iSperse formulation of the drug as a treatment for asthma patients who have developed allergic bronchopulmonary aspergillosis.
Get the full story at our sister site, Drug Delivery Business News.
The post Pulmatrix doses first patient in Ph1 Pulmazole trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 12, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news
